Details for Patent: 8,399,470

Title:	Inhibitors of bruton's tyrosine kinase
Abstract:	Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
Inventor(s):	Honigberg; Lee (San Francisco, CA), Verner; Erik (Belmont, CA), Pan; Zhengying (Austin, TX)
Assignee:	Pharmacyclics, Inc. (Sunnyvale, CA)
Filing Date:	Jan 30, 2012
Application Number:	13/361,733
Claims:	1. A compound of Formula (D) having the structure: ##STR00058## wherein: L.sub.a is CH.sub.2, O, NH, or S; Ar is a substituted or unsubstituted aryl, or a substituted or unsubstituted heteroaryl; Y is an optionally substituted group selected from among alkyl, heteroalkyl, aryl, and heteroaryl; Z is C(.dbd.O), OC(.dbd.O), NRC(.dbd.O), C(.dbd.S), S(.dbd.O).sub.x, OS(.dbd.O).sub.x, or NRS(.dbd.O).sub.x, where x is 1 or 2; R is H or C.sub.1-C.sub.6alkyl; and R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, substituted or unsubstituted C.sub.6-C.sub.12 arylene, or substituted or unsubstituted C.sub.3-C.sub.12 heteroarylene; R.sub.8 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, substituted or unsubstituted C.sub.6-C.sub.12 arylene, or substituted or unsubstituted C.sub.3-C.sub.12 heteroarylene; R.sub.6 is H, substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); or R.sub.7 and R.sub.8 taken together form a bond; R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl); or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, wherein L.sub.a is O. 3. The compound of claim 2, wherein Ar is phenyl. 4. The compound of claim 3, wherein Z is C(.dbd.O), NHC(.dbd.O), or S(.dbd.O).sub.2. 5. The compound of claim 4, wherein R.sub.6 and R.sub.8 are H; and R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl, substituted or unsubstituted C.sub.6-C.sub.12 arylene, or substituted or unsubstituted C.sub.3-C.sub.12 heteroarylene. 6. The compound of claim 5, wherein R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, or substituted or unsubstituted C.sub.2-C.sub.6heterocycloalkyl. 7. The compound of claim 6, wherein R.sub.7 is substituted or unsubstituted C.sub.1-C.sub.4alkyl. 8. The compound of claim 7, wherein C.sub.1-C.sub.4alkyl is substituted with a disubstituted amino group. 9. The compound of claim 8, wherein R.sub.7 is ##STR00059## 10. The compound of claim 4, wherein R.sub.7 and R.sub.8 taken together form a bond; and R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, substituted or unsubstituted C.sub.1-C.sub.4heteroalkylene, C.sub.1-C.sub.6alkoxyalkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl, substituted or unsubstituted heteroaryl, C.sub.1-C.sub.4alkyl(aryl), C.sub.1-C.sub.4alkyl(heteroaryl), C.sub.1-C.sub.4alkyl(C.sub.3-C.sub.8cycloalkyl), or C.sub.1-C.sub.4alkyl(C.sub.2-C.sub.8heterocycloalkyl). 11. The compound of claim 10, wherein R.sub.6 is substituted or unsubstituted C.sub.1-C.sub.4alkyl, C.sub.1-C.sub.8alkylaminoalkyl, substituted or unsubstituted C.sub.3-C.sub.6cycloalkyl, or substituted or unsubstituted C.sub.2-C.sub.8heterocycloalkyl. 12. The compound of claim 11, wherein R.sub.6 is ##STR00060## 13. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, and a pharmaceutically acceptable excipient. 14. The pharmaceutical composition of claim 13 that is formulated for a route of administration selected from oral administration, parenteral administration, buccal administration, nasal administration, topical administration, or rectal administration.